Please login to the form below

Not currently logged in
Email:
Password:

Vifor Pharma

This page shows the latest Vifor Pharma news and features for those working in and with pharma, biotech and healthcare.

AZ finally gets EU nod for Veltassa rival Lokelma

AZ finally gets EU nod for Veltassa rival Lokelma

challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... delaying approval and giving Vifor time to consolidate its position in the market.

Latest news

  • Novartis and Bayer among backers for European big data project Novartis and Bayer among backers for European big data project

    Novartis, Bayer, Servier and Vifor Pharma are among those participating in BigData@Heart, a five-year, 19m project supported by the Innovative Medicines Initiative (IMI). ... Digital inspiration for pharma on mobile, social media, strategy, best practice,

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Scott Garland, president of Relypsa, said: “We look forward to working with our

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    If approved it will also be sold by Vifor Pharma in the US dialysis market. ... Epogen shrank by a third last year thanks in part to switching of some patients to Amgen's long-acting ESA Aranesp (darbepoetin alfa) and competition from Roche/Vifor's

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    When AZ bought ZS Pharma it described ZS-9 as a "best in class" potassium-binder with sales potential in excess of $1bn a year. ... Galenica's Vifor Pharma unit - needing a black box warning on its US labelling.

  • Vifor launches digital tools for iron deficiency awareness Vifor launches digital tools for iron deficiency awareness

    Vifor Pharma has unveiled a new website and iPhone and Android mobile to support its efforts to raise awareness of iron deficiency among the third of the European population that ... Digital inspiration for pharma on mobile, social media, strategy, best

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Other pharma companies divesting assets this month include Janssen/J&J and Sanofi. ... In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the

  • Deal Watch July 2016 Deal Watch July 2016

    Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Galenica, the Swiss healthcare company that is preparing itself for a split into two parts, Vifor Pharma (healthcare product development, manufacturing and

  • Deal Watch May 2016 Deal Watch May 2016

    The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D prohormone treatment] from OPKO paying ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Hansa Medical poaches Vifor Pharma’ s CEO. Søren Tulstrup becomes the Swedish biopharma’s CEO and president. ... Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global

  • Swiss biotech Inositec appoints new chief medical officer Swiss biotech Inositec appoints new chief medical officer

    Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at

  • Galenica Group strengthens management team Galenica Group strengthens management team

    Stefan Schulze has been appointed as chief operating officer and president of the executive committee of Vifor Pharma, part of the Switzerland-based Galenica Group. ... We opted for these variant because of the excellent knowledge Stefan Schulze brings

  • Lupin appoints Thierry Volle president for EMEA Lupin appoints Thierry Volle president for EMEA

    Lupin appoints Thierry Volle president for EMEA. He moves to the company from Vifor. ... He joins the firm from Vifor Pharma, where he was the head of EU and International business operations, and prior to that he served at Wyeth.

  • Verona names David Ebsworth as non-executive chairman Verona names David Ebsworth as non-executive chairman

    Verona names David Ebsworth as non-executive chairman. He joins from Vifor Pharma. ... He most recently served as CEO at Vifor Pharma and was also named CEO of Galenica in 2011, continuing to be an adviser for both firms.

More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics